# Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Study · id `cardio:ct-nct02058147` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02058147](<https://clinicaltrials.gov/study/NCT02058147>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02058147

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1170 participants.

## Technical summary

Registry record NCT02058147. Randomized; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2017-02-10.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1170 participants (enrolled count; ClinicalTrials.gov record NCT02058147, source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02058147, source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)
- Primary completion: 2015-06 (actual) (ClinicalTrials.gov record NCT02058147, source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT02058147, source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)
- Results first posted: 2017-02-10 (ClinicalTrials.gov record NCT02058147, source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Canada; Chile; Czechia; Denmark; Estonia; France; Germany; Hungary; Italy; Latvia; Lithuania; Mexico; Poland; Romania; Russia; South Africa; Spain; Sweden; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02058147, source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02058147-2017-05-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
- Acronym: LixiLan-O
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin glargine/lixisenatide Fixed Ratio Combination
- Intervention (Drug): Insulin glargine (HOE901)
- Intervention (Drug): Lixisenatide (AVE0010)
- Intervention (Drug): Metformin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial (`cardio:pubmed-27527848`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents (`cardio:pubmed-28432746`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial (`cardio:pubmed-31124299`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: eeb8b695b21523e0a929d3211bddf872f2901cedd3bfdc8853475c773cc5fe16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
